Arvinas (NASDAQ: ARVN) revenue
Arvinas reported revenue of $262.6m for fiscal 2025, 0.3% less than in fiscal 2024 ($263.4m). Since fiscal 2017 its revenue has grown by 3,364.9%, an average growth of 55.8% a year.
Arvinas's best year of the last 9 was fiscal 2024. The biggest drop was in fiscal 2023, −40.3%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $262.6m | −0.3% | −$118.5m | −45.1% |
| 2024 | $263.4m | +235.5% | −$250.2m | −95.0% |
| 2023 | $78.5m | −40.3% | −$401.5m | −511.5% |
| 2022 | $131.4m | +145.1% | −$263.2m | −200.3% |
| 2021 | $53.6m | +106.9% | −$188.4m | −351.5% |
| 2020 | $25.9m | −39.8% | −$120.8m | −466.4% |
| 2019 | $43.0m | +200.2% | −$51.5m | −119.8% |
| 2018 | $14.3m | +89.0% | −$43.8m | −305.8% |
| 2017 | $7.6m | — | −$24.8m | −326.7% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Arvinas revenue compared with its sector
By revenue for its latest fiscal year, Arvinas ranks 231st of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Arvinas, −0.3%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 229th | Ligand Pharmaceuticals | $268.1m | 60.4% |
| 230th | Iovance Biotherapeutics | $263.5m | 60.6% |
| 231st | Arvinas | $262.6m | −0.3% |
| 232nd | Schrodinger | $255.9m | 23.3% |
| 233rd | LeMaitre Vascular | $249.6m | 13.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Arvinas
- How much revenue did Arvinas make in fiscal 2025?
- Arvinas reported revenue of $262.6m for fiscal 2025, compared with $263.4m in fiscal 2024.
- How much has the revenue of Arvinas grown?
- Between fiscal 2017 and fiscal 2025 it went from $7.6m to $262.6m: 3,364.9% more, an average growth of 55.8% a year.
- What was the best year for revenue at Arvinas?
- Of its last 9 fiscal years, fiscal 2024, with $263.4m.
- Where does Arvinas rank in its sector by revenue?
- It ranks 231st of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Arvinas come from?
- From the annual report (Form 10-K) that Arvinas files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Arvinas files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Arvinas: the Arvinas page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.